icon-folder.gif   Conference Reports for NATAP  
 
  63rd Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 9-12 2012
Back grey_arrow_rt.gif
 
 
 
Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Co-infected Patients: SVR24 Final Study Results
 
 
  Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
 
Mark S. Sulkowski1, Kenneth E. Sherman2, Vincent Soriano3, Jürgen K. Rockstroh4, Douglas T. Dieterich5, Pierre-Marie Girard6, Mohammad Bsharat7, Joshua Henshaw7, Raymond A. Rubin7, Varun Garg7, Nathalie Adda7
On behalf of the Study 110 Team
1Johns Hopkins University School of Medicine, Baltimore, MD, United States, 2University of Cincinnati College of Medicine, Cincinnati, OH, United States, 3Hospital Carlos III, Madrid, Spain, 4University of Bonn, Bonn, Germany, 5Mount Sinai School of Medicine, New York, NY, United States, 6Hôpital St Antoine, Paris, France, and 7Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States.

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif

AASLD12.gif